Clinical Trials

    Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

    Investigator: Jun Zhang

    Study Coordinator: Maria Gagliardi

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT06350097

    Phone: 832.475.2075

    Protocol Number: PRO00039188

    Description


    The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC.